Vivus Inc (VVUS) - Financial and Strategic SWOT Analysis Review

  • ID: 4308179
  • SWOT Analysis
  • 49 pages
  • GlobalData
  • Vivus
1 of 5

FEATURED COMPANIES

  • Arena Pharmaceuticals Inc
  • Eli Lilly and Co
  • GlaxoSmithKline Plc
  • Merck & Co Inc
  • Novo Nordisk AS
  • Orexigen Therapeutics Inc
  • MORE
Vivus Inc (VVUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Vivus Inc (Vivus) is a biopharmaceutical company which develops and commercializes next-generation therapeutics for addressing unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's marketed products include, Qsymia (phentermine and topiramate extended-release), indicated for the chronic weight management in adult patients; and Stendra/Spedra (avanafil), an oral phosphodiesterase type 5, for erectile dysfunction. Its pipeline products include Qsymia for obstructive sleep apnea, nonalcoholic steatohepatitis, diabetes, nonalcoholic fatty liver disease and hyperlipidemia; and Tacrolimus for pulmonary arterial hypertension. Vivus works in partnership with pharmaceutical companies to advance of its product portfolio. It operates through its subsidiaries in the UK, the Netherlands, Ireland and Bermuda. Vivus is headquartered in Campbell, California, the US.

Vivus Inc Key Recent Developments

Mar 13, 2018: VIVUS Reports Fourth Quarter 2017 Financial Results
Dec 26, 2017: VIVUS Announces Change in Leadership
Nov 07, 2017: VIVUS Reports Third Quarter 2017 Financial Results
Aug 03, 2017: VIVUS Reports Second Quarter 2017 Financial Results
May 24, 2017: Thomas B. King Joins VIVUS' Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Arena Pharmaceuticals Inc
  • Eli Lilly and Co
  • GlaxoSmithKline Plc
  • Merck & Co Inc
  • Novo Nordisk AS
  • Orexigen Therapeutics Inc
  • MORE
Section 1 - About the Company
  • Vivus Inc - Key Facts
  • Vivus Inc - Key Employees
  • Vivus Inc - Key Employee Biographies
  • Vivus Inc - Major Products and Services
  • Vivus Inc - History
  • Vivus Inc - Company Statement
  • Vivus Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Vivus Inc - Business Description
  • Vivus Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Vivus Inc - Strengths
  • Vivus Inc - Weaknesses
  • Vivus Inc - Opportunities
  • Vivus Inc - Threats
  • Vivus Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Vivus Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Vivus Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 13, 2018: VIVUS Reports Fourth Quarter 2017 Financial Results
  • Dec 26, 2017: VIVUS Announces Change in Leadership
  • Nov 07, 2017: VIVUS Reports Third Quarter 2017 Financial Results
  • Aug 03, 2017: VIVUS Reports Second Quarter 2017 Financial Results
  • May 24, 2017: Thomas B. King Joins VIVUS' Board of Directors
  • May 03, 2017: VIVUS Reports 2017 First Quarter Financial Results
  • Mar 08, 2017: VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Vivus Inc, Key Facts
  • Vivus Inc, Key Employees
  • Vivus Inc, Key Employee Biographies
  • Vivus Inc, Major Products and Services
  • Vivus Inc, History
  • Vivus Inc, Subsidiaries
  • Vivus Inc, Key Competitors
  • Vivus Inc, Ratios based on current share price
  • Vivus Inc, Annual Ratios
  • Vivus Inc, Annual Ratios
  • Vivus Inc, Annual Ratios
  • Vivus Inc, Interim Ratios
  • Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Vivus Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Vivus Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Vivus Inc, Performance Chart (2013 - 2017)
  • Vivus Inc, Ratio Charts
  • Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Vivus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Pfizer Inc
  • Orexigen Therapeutics Inc
  • Novo Nordisk AS
  • Merck & Co Inc
  • GlaxoSmithKline Plc
  • Eli Lilly and Co
  • Arena Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll